The Technical Analyst
Ardelyx Inc [ARDX]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Ardelyx Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-2.38% $6.55
America/New_York / 17 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 524.09 mill |
| EPS: | -0.300 |
| P/E: | -21.83 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 232.69 mill |
| Avg Daily Volume: | 5.63 mill |
| RATING 2024-04-17 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -21.83 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -3.71x |
| Company: PE -21.83 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 6.10 - 7.00 ( +/- 6.85%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-15 | Raab Michael | Sell | 7 500 | Common Stock |
| 2024-04-01 | Raab Michael | Sell | 1 518 | Common Stock |
| 2024-03-25 | Kelliher Mike | Buy | 205 000 | Stock Option (Right to Buy) |
| 2024-03-25 | Kelliher Mike | Buy | 160 000 | Common Stock |
| 2024-03-25 | Kelliher Mike | Buy | 0 |
| INSIDER POWER |
|---|
| 66.43 |
| Last 99 transactions |
| Buy: 4 000 095 | Sell: 852 364 |
Forecast:
16:00 - $6.56
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $6.56
Forecast 2: 16:00 - $6.56
Forecast 3: 16:00 - $6.56
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $6.55 (-2.38% ) |
| Volume | 3.58 mill |
| Avg. Vol. | 5.63 mill |
| % of Avg. Vol | 63.54 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ARDX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $9.34 | N/A | Active |
|---|
ARDX
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Last 10 Buy Signals
Latest Press Releases
2024-03-28 16:05:00 - Press Release
Ardelyx, Inc. Reports Employment Inducement Grants
Waltham, mass., march 28, 2024 (globe newswire) -- ardelyx, inc. (nasdaq: ardx), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on march 25, 2024, the compensation committee of the company's board of directors granted a non-qualified stock option award to purchase 205,000 shares of its common stock and a restricted stock unit award for 160,000 shares in connection with the commencement of employment of its new executive vice president, corporate development and strategy, michael kelliher. in addition, the compensation committee of the company's board of directors also granted 14 new non-executive employees options to purchase an aggregate of 400,500 shares of the company's common stock, and an aggregate of 283,725 restricted stock units (rsus)...
2024-03-25 08:00:00 - Press Release
Ardelyx Appoints Veteran Biopharma Executive, Mike Kelliher, As Executive Vice President, Corporate Development And Strategy
Waltham, mass., march 25, 2024 (globe newswire) -- ardelyx, inc. (nasdaq: ardx), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of mike kelliher to the position of executive vice president, corporate development and strategy. mr. kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.
2024-03-12 16:35:00 - Press Release
Ardelyx, Inc. Reports Employment Inducement Grants
Waltham, mass., march 12, 2024 (globe newswire) -- ardelyx, inc. (nasdaq: ardx), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on march 9, 2024, the compensation committee of the company's board of directors granted nine new non-executive employees options to purchase an aggregate of 207,038 shares of the company's common stock, and granted twelve new non-executive employees an aggregate of 157,450 restricted stock units (rsus). each stock option has an exercise price equal to $8.69 per share, which was the closing trading price of the company's common stock on the last trading date preceding the date of grant, which was a non-trading day...
2024-02-27 08:00:00 - Press Release
Ardelyx To Participate At The Cowen 44th Annual Health Care Conference
Waltham, mass., feb. 27, 2024 (globe newswire) -- ardelyx, inc. (nasdaq: ardx), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that susan rodriguez, chief commercial officer of ardelyx, will participate in a cardiorenal panel discussion at the cowen 44th annual health care conference on tuesday, march 5, 2024 at 10:30 a.m. eastern time in boston, ma.
2024-02-22 16:01:00 - Press Release
Ardelyx Reports Fourth Quarter And Full Year 2023 Financial Results And Provides Business Update
Strong commercial performance of ibsrela continues, ending fy 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million
Latest News
2024-04-02 11:34:07 - InvestorPlace
The Millionaire's Shortcut: 3 Stocks to Transform Your Portfolio This Month
The stock market has performed remarkably well lately. Within the last 12 months, the S&P 500, a benchmark representation of the U.S. stock market comprised of the 500 largest publicly traded companies, has increased by 26%.
2024-03-21 14:08:38 - Schaeffers Research
Bull Signal Says Buy This Biopharmaceutical Stock Now
Ardelyx Inc (NASDAQ:ARDX) stock was last seen 0.6% lower at $7.75, extending a pullback from its Feb. 12, nearly seven-year high of $10.13.
2024-03-16 18:00:00 - InvestorPlace
The Clock is Ticking: 3 Stocks Set to Explode in the Next Quarter
Finding the next great investment is alluring, almost like a siren's song. For this, one must possess a crystal ball to identify the stocks about to soar, elevating portfolios to unprecedented heights.
2024-03-13 18:00:47 - Seeking Alpha
Ardelyx Shrugs Off 'Mixed' Q4 Earnings
Shares tanked 16% within the first 18 minutes of the press release, and dipped even lower in pre-market trading. Market sentiment was countered by bullish stances from at least four firms. Yet Wall Street continues to be oblivious, with only one of them mentioning XPHOZAH revenue contributions. UpToDate, the leading clinical decision tool for most doctors, supports the use of XPHOZAH.
2024-02-28 17:40:00 - InvestorPlace
The Millionaire's Watchlist: 3 Stocks Set for a Meteoric Rise
In the stock market, identifying potential millionaire-making stocks can lead to a situation like finding needles in a haystack. However, under ongoing volatility, three companies have emerged as prime contenders for high returns.
2024-02-27 06:10:00 - InvestorPlace
Stocks on the Launchpad: The Next 3 Market Sensations
In the current bullish stock market, it's an exhilarating period for savvy investors betting on the upcoming market sensations. The optimism is connected to the S&P 500 shattering the historic 5000 threshold, supported by the U.S. Federal Reserve's bullish projection of 2.9% growth in the first quarter (Q1).
2024-02-22 20:23:14 - Seeking Alpha
Ardelyx, Inc. (ARDX) Q4 2023 Earnings Call Transcript
2024-02-22 19:01:33 - Zacks Investment Research
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Ardelyx (ARDX) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2024-02-22 18:16:08 - Zacks Investment Research
Ardelyx (ARDX) Reports Q4 Loss, Lags Revenue Estimates
Ardelyx (ARDX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.06 per share a year ago.
2024-02-19 15:30:00 - InvestorPlace
Analyst Upgrades: 3 Stocks Predicted to Soar In Q2 2024
Analyst upgrades consistently offer valuable insights, deftly guiding investors through market dynamics. 2024 unfolds a promising economic landscape, diverging from past apprehensions.